Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:2017:5126048.
doi: 10.1155/2017/5126048. Epub 2017 Aug 9.

The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer

Affiliations
Review

The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer

Chengxin Luo et al. Mediators Inflamm. 2017.

Abstract

Patients with inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer (CRC). The risk factors of CRC in IBD patients include long disease duration, extensive colitis, severe histological inflammation, and coexistence with primary sclerosing cholangitis (PSC). Several molecular pathways that contribute to sporadic CRC are also involved in the pathogenesis of colitis-associated CRC. It is well established that long-standing chronic inflammation is a key predisposing factor of CRC in IBD. Proinflammatory pathways, including nuclear factor kappa B (NF-κB), IL-6/STAT3, cyclooxygenase-2 (COX-2)/PGE2, and IL-23/Th17, promote tumorigenesis by inducing the production of inflammatory mediators, upregulating the expression of antiapoptotic genes, and stimulating cell proliferation as well as angiogenesis. Better understanding of the underlying mechanisms may provide some promising targets for prevention and therapy. This review aims to elucidate the role of these signaling pathways in the pathogenesis of colitis-associated CRC using evidence-based approaches.

PubMed Disclaimer

Figures

Figure 1
Figure 1
NF-κB pathway functions as the molecular link between inflammation and tumorigenesis. NF-κB pathway can be activated by proinflammatory cytokines (TNF-α and IL-1), bacterial components (such as LPS), viruses, and DNA-damaging agents. Activation of NF-κB pathway induces expression of proinflammatory cytokines (such as TNF-α, IL-1, and IL-6), chemokines (IL-8), and enzymes (COX-2) that contribute to inflammation-related tissue damages and are associated with tumor initiation. Antiapoptotic factors GADD45β, BFL1, and BCL-XL ensure tumor cell survival and proliferation. In addition, VEGF, COX-2, and IL-8 promote angiogenesis and play an important role in tumor progression. MMP-9 contributes to tumor progression through facilitating metastasis.
Figure 2
Figure 2
The role of COX-2/PGE2 pathway in colitis-associated CRC. The COX enzymes catalyze the biosynthesis of PGG2 and PGH2 from arachidonic acid. PGH2 is subsequently metabolized to TXA2, PGI2, PGE2, PGD2, and PGF2α by PG synthases. COX-2-derived PGE2 acts via specific receptor EP1-4 and plays an important role in tumor development and progression through inducing expression of antiapoptotic proteins (such as BCL-2), proangiogenic chemokines (such as CXCL1), and MMP. In addition, PGE2 mediates the activation of PPARδ through PI3K/Akt signaling. PPARδ contributes to tumorigenesis by ensuring tumor cell survival and proliferation. Activation of PPARδ can further enhance the production of COX-2-derived PGE2.

Similar articles

Cited by

References

    1. Ullman T., Odze R., Farraye F. A. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn’s disease of the colon. Inflammatory Bowel Diseases. 2009;15:630–638. doi: 10.1002/ibd.20766. - DOI - PMC - PubMed
    1. Eaden J. A., Abrams K. R., Mayberry J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535. - PMC - PubMed
    1. Castano-Milla C., Chaparro M., Gisbert J. P. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2014;39:645–659. doi: 10.1111/apt.12651. - DOI - PubMed
    1. Canavan C., Abrams K. R., Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Alimentary Pharmacology & Therapeutics. 2006;23:1097–1104. - PubMed
    1. Sebastian S., Hernandez V., Myrelid P., et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I) Journal of Crohn's & Colitis. 2014;8:5–18. doi: 10.1016/j.crohns.2013.04.008. - DOI - PubMed

MeSH terms